RxDoctor Payments DataLook up a doctor →

Michelle Welch, MD

Endocrinology, Diabetes & Metabolism · Shavano Park, TXNPI 1891764957

Payments from drug & device makers

$17,298,481in general payments, 2019–2025

Across 4,771 payments — averaging $3625.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$12.6M
  • AstraZeneca$1.2M
  • Novo Nordisk AS$708K
  • Pfizer$564K
  • Regeneron$517K
  • AbbVie$371K
  • plus $1.3M from 54 others
$222,000in research payments, 2019–2025

Across 41 payments — averaging $5414.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$222K
  • Novo Nordisk$48

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly355$12,572,071
AstraZeneca(2 entities)231$1,230,016
Novo Nordisk AS2,104$708,458
Pfizer105$563,772
Regeneron80$516,746
AbbVie(2 entities)141$370,761
Boehringer Ingelheim105$328,477
Lilly USA, LLC374$226,341
Genentech, Inc.36$219,914
Novartis21$139,842
Amgen(2 entities)124$70,893
Hoffmann-la Roche Limited10$60,786
Senseonics, Incorporated9$52,259
Sanofi US Services Inc.4$49,281
Boehringer Ingelheim International GmbH228$41,986
Kowa Research Institute, Inc.25$33,262
F. Hoffmann-la Roche AG5$19,289
Bayer9$13,409
Sanofi-aventis U.S. LLC68$11,609
Mannkind Corporation99$11,548
GSK1$10,058
Johnson & Johnson22$9,837
Eli Lilly Export S.A. Puerto Rico Branch4$8,991
Boehringer Ingelheim Pharma GmbH & Co.kg1$6,677
Cequr Corporation7$4,876
Novo Nordisk162$2,808
Dexcom, Inc.35$1,778
Lexicon Pharmaceuticals, Inc.1$1,600
Medtronic(2 entities)8$1,568
Abbott47$999
Sequel Med Tech, LLC14$734
Tandem Diabetes Care, Inc.11$588
Insulet Corporation32$584
BETA Bionics, Inc.10$578
Antares Pharma, Inc.46$573
Ascensia Diabetes Care US Inc.6$519
Radius Health, Inc.15$483
Corcept Therapeutics25$425
Amarin Pharma, Inc.28$410
Regeneron Healthcare Solutions, Inc.11$374
Zealand Pharma US, Inc.12$358
Xeris Pharmaceuticals, Inc.13$323
Madrigal Pharmaceuticals9$300
Recordati_rare_diseases_inc.5$211
Averitas Pharma Inc.5$191
Esperion Therapeutics, Inc.14$157
Nalpropion Pharmaceuticals LLC9$126
Valeritas, Inc.9$118
EUSA Pharma (US) LLC2$116
Janssen Scientific Affairs, LLC3$115
Intuity Medical Inc7$107
Echosens North America, Inc.1$99
Merck7$96
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$75
Clarus Therapeutics Inc.4$62
IBSA Pharma Inc.4$58
Currax Pharmaceuticals LLC4$58
Strongbridge US Inc.2$54
Acerus Pharmaceuticals Corporation4$54
Kyowa Kirin, Inc.3$52

How this compares

$17,298,481 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.

See all endocrinology, diabetes & metabolism providers in Texas →

Medicare billing

Part B allowed, 2024
$501,986
Medicare patients
750
Services billed
6,721

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Shavano Park

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →